Giulia Martini

4.0k total citations · 1 hit paper
83 papers, 2.1k citations indexed

About

Giulia Martini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Giulia Martini has authored 83 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 17 papers in Molecular Biology. Recurrent topics in Giulia Martini's work include Colorectal Cancer Treatments and Studies (50 papers), Lung Cancer Treatments and Mutations (23 papers) and Cancer Genomics and Diagnostics (16 papers). Giulia Martini is often cited by papers focused on Colorectal Cancer Treatments and Studies (50 papers), Lung Cancer Treatments and Mutations (23 papers) and Cancer Genomics and Diagnostics (16 papers). Giulia Martini collaborates with scholars based in Italy, Spain and Germany. Giulia Martini's co-authors include Davide Ciardiello, Stefania Napolitano, Teresa Troiani, Fortunato Ciardiello, Claudia Cardone, Fortunato Ciardiello, Josep Tabernero, Pietro Paolo Vitiello, Floriana Morgillo and Andrés Cervantes and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Giulia Martini

79 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical management of metastatic colorectal cancer in the era of precision medicine

2022 336 citations Fortunato Ciardiello, Davide Ciardiello et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giulia Martini Italy	24	1.4k	793	565	494	429	83	2.1k
Davide Ciardiello Italy	22	1.4k 1.0×	803 1.0×	496 0.9×	496 1.0×	407 0.9×	86	2.2k
Fortunato Ciardiello Italy	23	1.7k 1.2×	435 0.5×	697 1.2×	456 0.9×	537 1.3×	79	2.3k
Tormod Kyrre Guren Norway	29	1.3k 1.0×	990 1.2×	515 0.9×	638 1.3×	428 1.0×	80	2.5k
Rachel Midgley United Kingdom	26	1.7k 1.2×	929 1.2×	440 0.8×	559 1.1×	671 1.6×	56	2.8k
Monica Motwani United States	22	1.2k 0.9×	895 1.1×	577 1.0×	302 0.6×	371 0.9×	45	2.0k
Stephen Leong United States	23	1.1k 0.8×	842 1.1×	471 0.8×	606 1.2×	218 0.5×	73	2.3k
Claudio Isella Italy	24	1.1k 0.8×	1.2k 1.5×	297 0.5×	915 1.9×	416 1.0×	50	2.3k
Tomislav Dragovich United States	24	1.1k 0.8×	1.0k 1.3×	548 1.0×	444 0.9×	230 0.5×	80	2.3k
Agustin A. García United States	31	1.5k 1.1×	1.1k 1.4×	681 1.2×	392 0.8×	448 1.0×	114	3.1k
Xichun Hu China	28	1.3k 1.0×	1.2k 1.5×	770 1.4×	715 1.4×	232 0.5×	155	2.8k

Countries citing papers authored by Giulia Martini

Since Specialization

Citations

This map shows the geographic impact of Giulia Martini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giulia Martini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giulia Martini more than expected).

Fields of papers citing papers by Giulia Martini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giulia Martini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giulia Martini. The network helps show where Giulia Martini may publish in the future.

Co-authorship network of co-authors of Giulia Martini

This figure shows the co-authorship network connecting the top 25 collaborators of Giulia Martini. A scholar is included among the top collaborators of Giulia Martini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giulia Martini. Giulia Martini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Troiani, Teresa, Evaristo Maiello, Antonio Avallone, et al.. (2024). 114P Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial. ESMO Open. 9. 103853–103853. 2 indexed citations

Martini, Giulia, Davide Ciardiello, Stefania Napolitano, et al.. (2023). Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial. Frontiers in Oncology. 13. 1069370–1069370. 8 indexed citations

Ciardiello, Davide, Stefania Napolitano, Vincenzo Famiglietti, et al.. (2023). Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials. Cancers. 15(7). 2117–2117. 6 indexed citations

Ciardiello, Fortunato, et al.. (2023). Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. SHILAP Revista de lepidopterología. 4(1). 102–138. 39 indexed citations

Ciardiello, Davide, Gianluca Mauri, Daniele Rossini, et al.. (2023). 559MO Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wild type refractory metastatic colorectal cancer: Individual patients’ data pooled analysis from 4 phase II trials. Annals of Oncology. 34. S416–S416. 3 indexed citations

Dardi, Fabio, Sofia Martìn Suàrez, Antonio Loforte, et al.. (2023). Comparison of different treatment strategies in patients with chronic thromboembolic pulmonary hypertension: a single centre real-world experience. International Journal of Cardiology. 391. 131333–131333. 2 indexed citations

Martini, Giulia, Davide Ciardiello, Marcello Dallio, et al.. (2022). Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab. International Journal of Cancer. 151(3). 473–480. 52 indexed citations

Napolitano, Stefania, Giulia Martini, Davide Ciardiello, et al.. (2022). CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients. Frontiers in Oncology. 12. 940523–940523. 16 indexed citations

Martini, Giulia, Davide Ciardiello, Fabrizio Urraro, et al.. (2021). How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. Cancers. 13(18). 4719–4719. 9 indexed citations

10.

Ros, Javier, Iosune Baraibar, Giulia Martini, et al.. (2021). The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Current Treatment Options in Oncology. 22(12). 113–113. 14 indexed citations

11.

Elez, Élena, Javier Ros, Giulia Martini, et al.. (2021). LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR +/- MEK inhibitors. Annals of Oncology. 32. S226–S227. 10 indexed citations

12.

Insa, Amelia, Paloma Martín-Martorell, Raimondo Di Liello, et al.. (2021). Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. Critical Reviews in Oncology/Hematology. 169. 103538–103538. 23 indexed citations

13.

Martini, Giulia, Emilio Bria, Cesare Gridelli, et al.. (2020). 1808TiP Atezolizumab (ATZ) in combination with carboplatin (Cb) and etoposide (Eto) in the treatment of patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC): A multicenter, phase IIIb, single arm, safety study (MAURIS trial). Annals of Oncology. 31. S1044–S1045. 6 indexed citations

14.

Martinelli, Erika, Davide Ciardiello, Giulia Martini, et al.. (2020). Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Annals of Oncology. 31(1). 30–40. 126 indexed citations

15.

Martinelli, Erika, Giulia Martini, Teresa Troiani, et al.. (2020). 397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study. Annals of Oncology. 31. S409–S410. 16 indexed citations

16.

Martini, Giulia, et al.. (2019). How I treat anal squamous cell carcinoma. ESMO Open. 4(Suppl 2). e000711–e000711. 4 indexed citations

17.

Sforza, Vincenzo, Erika Martinelli, Claudia Cardone, et al.. (2017). Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. ESMO Open. 2(4). e000229–e000229. 13 indexed citations

18.

Cardone, Claudia, Mariel C. Paul, Verónica Moreno‐Viedma, et al.. (2017). Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial. Annals of Oncology. 28. v576–v576. 1 indexed citations

19.

Sforza, Vincenzo, Erika Martinelli, Fortunato Ciardiello, et al.. (2016). Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World Journal of Gastroenterology. 22(28). 6345–6345. 90 indexed citations

20.

Martini, Giulia, Valentina Belli, Pietro Paolo Vitiello, et al.. (2016). blockade overcomes primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (mCRC). Annals of Oncology. 27. vi1–vi1. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact